Evidence map›Paper›PMID 36558888›Full record

ArticlePathogens (Basel, Switzerland)2022

Type I Interferon Signaling Controls Gammaherpesvirus Latency In Vivo.

Johannes Schwerk, Lucas Kemper, Kendra A Bussey, Stefan Lienenklaus, Siegfried Weiss, Luka Čičin-Šain, Andrea Kröger, Ulrich Kalinke, Christopher M Collins, Samuel H Speck and 5 more

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Mouse Models for Human Herpesviruses.Pathogens (Basel, Switzerland) · 2023
    Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Johannes SchwerkModel System for Infection and Immunity, Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany.ORCID 0000-0002-5964-7162
Lucas KemperModel System for Infection and Immunity, Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany.
Kendra A BusseyInstitute of Genetics, Technische Universität Braunschweig, 38106 Braunschweig, Germany.
Stefan LienenklausInstitute for Laboratory Animal Science, Hannover Medical School, 30625 Hannover, Germany.
Siegfried WeissInstitute of Immunology, Hannover Medical School, 30625 Hannover, Germany.
Luka Čičin-ŠainViral Immunology, Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany.ORCID 0000-0003-3978-778X
Andrea KrögerInnate Immunity and Infection, Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany.
Ulrich KalinkeInstitute for Experimental Infection Research, Twincore, 30625 Hannover, Germany.ORCID 0000-0003-0503-9564
Christopher M CollinsDepartment of Microbiology & Immunology, Emory University Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.
Samuel H SpeckDepartment of Microbiology & Immunology, Emory University Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.
Martin MesserleDepartment of Virology, Hannover Medical School, 30625 Hannover, Germany.ORCID 0000-0002-1227-3933
Dagmar WirthModel System for Infection and Immunity, Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany.
Melanie M BrinkmannInstitute of Genetics, Technische Universität Braunschweig, 38106 Braunschweig, Germany.ORCID 0000-0001-5431-6527
Hansjörg HauserModel System for Infection and Immunity, Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany.
Mario KösterModel System for Infection and Immunity, Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany.
Helmholtz Centre for Infection Research · DEMedizinische Hochschule Hannover · DEEmory University · USCenter for Experimental and Clinical Infection Research · DE

Funding

Deutsche Forschungsgemeinschaft Cluster of Excellence REBIRTH; research grant Ho 2236/8-1; SPP1656; Collaborative Research Center SFB900German Ministry of Education and Research 01KI1003DNiedersächsisches Ministerium für Wissenschaft und Kultur 80029155
6 · The paper itself

Abstract

Gammaherpesviruses, such as Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus, are important human pathogens involved in lymphoproliferative disorders and tumorigenesis. Herpesvirus infections are characterized by a biphasic cycle comprised of an acute phase with lytic replication and a latent state. Murine gammaherpesvirus 68 (MHV-68) is a well-established model for the study of lytic and latent life cycles in the mouse. We investigated the interplay between the type I interferon (IFN)-mediated innate immune response and MHV-68 latency using sensitive bioluminescent reporter mice. Adoptive transfer of latently infected splenocytes into type I IFN receptor-deficient mice led to a loss of latency control. This was revealed by robust viral propagation and dissemination of MHV-68, which coincided with type I IFN reporter induction. Despite MHV-68 latency control by IFN, the continuous low-level cell-to-cell transmission of MHV-68 was detected in the presence of IFN signaling, indicating that IFN cannot fully prevent viral dissemination during latency. Moreover, impaired type I IFN signaling in latently infected splenocytes increased the risk of virus reactivation, demonstrating that IFN directly controls MHV-68 latency in infected cells. Overall, our data show that locally constrained type I IFN responses control the cellular reservoir of latency, as well as the distribution of latent infection to potential new target cells.

Indexed as

chronic infectionlatencymurine gammaherpesvirus 68type I interferon

Identifiers

PMID36558888
PMCPMC9787724
OpenAlexW4312211119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.